Clinical trials: Treatment Resistant Hypertension
Hypertension, Pulmonary, Lung Diseases, Interstitial
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
The primary purpose of this study is to assess the effect of TX000045 on pulmonary vascular resistance (PVR) in participants with pulmonary hypertension secondary to interstitial lung disease (PH-ILD) and to assess the safety and…
- Trial name
- NCT07473700
- Testing
- TX000045
- Where
- 16 sites in United States, Poland and 4 more
- Volunteers
- 25 people
- Sponsor
- Tectonic Operating Company, Inc.
PAH, Pulmonary Hypertension
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health…
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03626688
- Testing
- Ralinepag
- Where
- 209 sites in United States, Argentina and 31 more
- Volunteers
- 687 people
- Sponsor
- United Therapeutics
Hypertension
Carotid Body Removal for the Treatment of Resistant Hypertension: a Pilot Study
This is a pilot study to assess the effectiveness, safety and feasibility of carotid body removal in patients with high blood pressure (hypertension) resistant to medical treatment.
- Trial name
- NCT01729988
- Testing
- Carotid body excision
- Where
- Poland
- Volunteers
- 11 people
- Sponsor
- Noblewell
High Blood Pressure
Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension
To assess the long-term safety and efficacy of the BAROSTIM NEO System in trial (NCT01471834) participants.
- Trial name
- NCT01471834
- Testing
- BAROSTIM NEO System, Medical Management
- Where
- 9 sites in Canada, Germany and 1 more
- Volunteers
- 40 people
- Sponsor
- CVRx, Inc.
Hypertension
Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension
The primary objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40mg + amlodipine 10mg (T40/A10) or the fixed dose combination of telmisartan 80mg + amlodipine 10mg (T80/A10) is superior in…
- Trial name
- NCT00553267
- Testing
- fixed dose combination of telmisartan+amlodipine, amlodipine
- Where
- 97 sites in Australia, Austria and 12 more
- Volunteers
- 947 people
- Sponsor
- Boehringer Ingelheim
Hypertension
BAROSTIM THERAPY™ In Resistant Hypertension
The purpose of this registry (NCT02880631) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant…
- Trial name
- NCT02880631
- Testing
- BAROSTIM NEO™ System
- Where
- 26 sites in Germany, Netherlands
- Volunteers
- 500 people
- Sponsor
- CVRx, Inc.
Multivessel Coronary Artery Disease, Hypertension Resistant to Conventional Therapy
Expand Management of Blood Pressure With Renal Denervation in Patients Undergoing Staged PCI for Advanced Coronary Artery diseasE
EMBRACE is a randomized, controlled, multicenter clinical study evaluating the effect of renal denervation on clinical adverse events in hypertensive patients undergoing staged percutaneous coronary intervention (PCI) for…
- Trial name
- EMBRACE (NCT07602790)
- Testing
- Renal denervation
- Volunteers
- 1,000 people
- Sponsor
- Ceric Sàrl
Hypertension
Endovascular Carotid Body Ablation in Patients With Treatment- Resistant Hypertension: A Safety and Feasibility Study
This is a prospective, observational, multicenter trial to evaluate the safety and feasibility of selective endovascular unilateral carotid body ablation in patients with treatment-resistant hypertension.
- Trial name
- NCT02099851
- Testing
- Carotid body ablation (Cibiem)
- Where
- 2 sites in Czechia, Poland
- Volunteers
- 6 people
- Sponsor
- Noblewell
Hypertension, Uncontrolled Hypertension
SMART Study in Real World
This study is a multicenter, single-arm, open-label and post-market study in a real world patient population with uncontrolled hypertension to document the long-term safety and efficacy of a renal mapping/selective renal…
- Conditions
- Hypertension, Uncontrolled Hypertension, Resistant Hypertension, Reduce Antihypertensive Drug Burden
- Trial name
- SMART-RW (NCT06780696)
- Testing
- SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- SyMap Medical (Suzhou), Ltd.
Pulmonary Arterial Hypertension
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
The purpose of this study was to investigate the effects of QTI571 (imatinib) on pharmacokinetics of bosentan and sildenafil at steady state when co-administered to participants with pulmonary arterial hypertension.
- Trial name
- NCT01392469
- Testing
- Imatinib, Sildenafil, Bosentan
- Where
- 11 sites in United States, Australia and 5 more
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Resistant to Conventional Therapy
Safety and Efficacy Study of Extracorporeal Shockwave Therapy in the Treatment of Patients With Resistant Hypertension
Low intensity shockwaves have been proven in animal and human studies to increase tissue perfusion, promote angiogenesis and tissue regeneration and improve neural function.
- Trial name
- RHT (NCT02042066)
- Testing
- Omnispec model Vascuspec
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Medispec
Hypertension
Device Based Therapy in Hypertension Trial
The purpose of this study is to demonstrate the safety and efficacy of the Rheos Baroreflex Hypertension Therapy System in patients with refractory hypertension.
- Trial name
- DEBuT-HT (NCT00710190)
- Testing
- Rheos Baroreflex Hypertension Therapy System
- Where
- 9 sites in Czechia, Germany and 4 more
- Volunteers
- 46 people
- Sponsor
- CVRx, Inc.
Hypertension
DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension
This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the U.S., which means that a doctor cannot…
- Trial name
- Darusentan (NCT00353574)
- Testing
- Darusentan
- Where
- 75 sites in United States, Argentina and 6 more
- Volunteers
- 282 people
- Sponsor
- Gilead Sciences
Uncontrolled Hypertension
Netrod-Pilot Study of Renal Denervation With NetrodTM Sixelectrode Radiofrequency RDN System
This single-arm, non-randomized, open-label investigation aims to collect safety and efficacy data of the CE-Marked Netrod™ RDN System in treating European patients with primary hypertension in the absence of anti-hypertensive…
- Trial name
- NCT07061054
- Testing
- Netrod™ six-electrode radiofrequency renal denervation system
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
Obesity, Hypertension
Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.
The purpose of this study is to determine the efficacy of candesartan, once daily (QD), combined with hydrochlorothiazide to lower blood pressure in insulin-resistant, obese patients with hypertension.
- Trial name
- NCT00775814
- Testing
- Candesartan and Hydrochlorothiazide, Hydrochlorothiazide (HCT)
- Where
- 24 sites in Germany
- Volunteers
- 188 people
- Sponsor
- Takeda
Resistant Hypertension
Treatment of Resistant Hypertension: Cohort Study
This is a multicenter, prospective observational cohort study. It will compare effectiveness and safety of various add-on treatment options in regard to arterial blood pressure control in adult patients with treatment resistant…
- Trial name
- TRYCORT (NCT05087940)
- Testing
- Add-on therapy
- Where
- 12 sites in Serbia
- Volunteers
- 731 people
- Sponsor
- Galenika AD Beograd
Hypertension Resistant to Conventional Therapy, Bradycardia
Moderato System: A Double-Blind Randomized Trial Ver 1.1
The purpose of this double blind randomized study is the evaluation of the safety and efficacy of the Moderato System. The Moderato implantable pulse generator is indicated for patients who have hypertension and also require a…
- Conditions
- Hypertension Resistant to Conventional Therapy, Bradycardia, Atrioventricular Block
- Trial name
- NCT02837445
- Testing
- PHC ON, PHC OFF
- Where
- 12 sites in Austria, Belgium and 5 more
- Volunteers
- 70 people
- Sponsor
- BackBeat Medical Inc
Pulmonary Arterial Hypertension
CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension
This Phase 2 study (EPIMODE) will evaluate the efficacy and safety of CS1 compared with placebo when added to standard-of-care therapy in participants with pulmonary arterial hypertension.
- Trial name
- EPIMODE (NCT07761572)
- Testing
- CS1
- Volunteers
- 126 people
- Sponsor
- Cereno Scientific AB
Metabolic Syndrome, Hypertension
Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome
The purpose of this clinical research study is to learn if irbesartan is superior to hydrochlorothiazide relative to effects on insulin sensitivity and glucose metabolism in hypertensive patients with metabolic syndrome.
- Trial name
- NCT00110422
- Testing
- Irbesartan, Hydrochlorothiazide
- Where
- 25 sites in France, Germany and 4 more
- Volunteers
- 400 people
- Sponsor
- Bristol-Myers Squibb
Resistant Hypertension
Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension
HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with…
- Trial name
- NCT06526858
- Testing
- HyperQureTM Renal Denervation (RDN) System:
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- DeepQure Inc.